HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$120.55
−0.79%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$122.19
From 52W high−0.79%
Volume1.10M
Market cap$13.68B
P/E (TTM)34.2x
P/S (TTM)8.2x
Div yield—
Key dataOct 16, 2026
Open
$122.19
From 52W high
−0.79%
Volume
1.10M
Market cap
$13.68B
ValuationView details →
P/E (Fwd)
12.1x
EV/EBITDA
21.7x
P/E (TTM)
34.2x
RSI (14)
70.3
MomentumView details →
1D Return
−0.79%
YTD Return
+81.04%
SummaryUpdated Jun 1, 2026
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a San Diego-based biopharma technology platform company founded in 1998 that went public in 2004. The company has evolved from a traditional biotechnology firm into a specialized drug delivery technology platform, leveraging its proprietary ENHANZE technology to enable pharmaceutical companies to convert intravenous biologics into more convenient subcutaneous formulations. Over the past decade, Halozyme has transformed its business model from primarily developing its own drugs to licensing its platform technology to major pharmaceutical partners, creating a highly scalable and profitable royalty-based revenue stream.
Similar companies
Latest newsMore news →
Halozyme expanded its ENHANZE collaboration and licensing agreement with ARGENX SE to cover eight targets, creating eligibility for additional milestone payments and royalties.9d agoMerck & Co., Inc. found Merck to infringe Halozyme's EP 2,797,622 patent and enjoined MSD AG from manufacturing, marketing, using, importing or stocking Keytruda SC in eight European markets.9d ago